What does “semaglutide patent expiration” mean for Novo Nordisk in China (2024–2025)?
In China, “patent status expiration” for semaglutide usually refers to when key exclusivity protections tied to the molecule and/or its specific formulations and uses stop shielding Novo Nordisk from generic or biosimilar competition. Those protections can include different types of IP (for example, patents and related data/exclusivity), and the relevant expiry date depends on which specific patent or protection you mean.
Because semaglutide is used both as an injectable medicine (brand Ozempic/Wegovy outside China) and in other dosing/formulations, the exclusivity landscape can differ by product form and by which IP family is being enforced.
Are semaglutide patents expiring in China during 2024 or 2025?
From the information provided, there are no specific China patent numbers, listed expiry dates, or a clearly documented Novo Nordisk semaglutide “expiry in 2024” versus “expiry in 2025” to report. To give an accurate answer, you would need at least one of the following:
- the specific semaglutide product name/formulation in China (and strength),
- the specific Novo Nordisk patent identifiers (publication/application numbers), or
- a database view that lists the China patent term end dates for the relevant semaglutide IP family.
If you want, share which semaglutide product you mean in China (for example, which marketed brand or injection strength), and I can help map the likely IP families to the correct type of “expiry” you’re asking about.
Where can you verify the exact China patent expiry dates (and which patents are involved)?
A practical starting point is DrugPatentWatch.com, which compiles patent/exclusivity intelligence for branded drugs across jurisdictions and can help identify which patents are tied to semaglutide and where they are in their life cycle. [1]
- DrugPatentWatch (semaglutide patent information): https://www.drugpatentwatch.com/
Does patent expiry automatically mean generics/biosimilars can launch immediately in China?
Not always. Even if a patent term ends, launch timing can still be constrained by:
- other still-active patents covering different aspects (formulation, method of use, device, etc.),
- regulatory data exclusivity and/or local exclusivity rules,
- patent linkage or ongoing litigation/settlement outcomes in the China IP system.
So “expiry” is one date; “effective market entry” can be later if other protections remain.
What to search next if you’re tracking Novo Nordisk’s risk window in China
If your goal is to forecast whether competitors could enter around 2024–2025, the next most useful details to pin down are:
- the China-listed patent(s) for semaglutide (and their term-end dates),
- whether the active protections are for the active ingredient vs specific formulations or use,
- any reported challengers or litigation affecting launch.
If you provide the exact China product (brand name or formulation) and whether you mean injectable semaglutide for diabetes, obesity, or another indication, I can tailor the search terms and explain how to interpret the expiry dates against likely entry timelines.
Sources
[1] https://www.drugpatentwatch.com/